Myriad Genetics (MYGN) Tops Q4 EPS by 6c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $6.02 --0%
Financial Fact:
Income tax provision (benefit): 5.2M
Today's EPS Names:
XFOR, MG, YORW, More
Financial Fact:
Income tax provision (benefit): 5.2M
Today's EPS Names:
XFOR, MG, YORW, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.04, $0.06 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $209.8 million versus the consensus estimate of $207.17 million.
GUIDANCE:
Myriad Genetics sees Q1 2026 revenue of $200-203 million, versus the consensus of $211.3 million.
Myriad Genetics sees FY2026 revenue of $860-880 million, versus the consensus of $869.5 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oscar Health Inc. (OSCR) Tops Q3 EPS by 63c ; Offers Guidance
- Cigna Corp. (CI) Tops Q3 EPS by 46c, Beats on Revenue; Offers FY26 EPS Guidance
- Celsius Holdings Inc. (CELH) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
